Artificial intelligence will better assist in drug regulation

On the 2nd, the National Medical Products Administration released the "Implementation Opinions on 'Artificial Intelligence+Drug Supervision'" (hereinafter referred to as the "Opinions"), focusing on the key tasks of drug supervision reform, with the goal of modernizing drug supervision, and proposing seven key directions for the next stage of regulatory digitization. Based on the new trend of artificial intelligence technology development, five key tasks are proposed to strengthen the basic support of "artificial intelligence+drug supervision".

The Opinion proposes that by 2030, a preliminary integrated innovation system of drug supervision and artificial intelligence will be established, and the operation and management mechanism of "artificial intelligence+drug supervision" will be basically formed. The computing power support base will be more intensive and efficient, and high-quality datasets, vertical large models, and intelligent agents that meet the needs of intelligent supervision will be formed. Artificial intelligence will be effectively applied in scenarios such as review and approval, supervision and inspection, inspection and monitoring, and government services. The efficiency of human-machine collaboration will be significantly improved, and the full life cycle digital intelligent supervision capability will reach a new level. By 2035, a new pattern of intelligent drug safety governance driven by digital intelligence, intelligent agility, autonomous controllability, and ecological collaboration will be basically formed.